SCHEDULE: Armistice Capital Discloses 7.8% Stake in Revelation Biosciences

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 323,241 shares, representing 7.80% of the outstanding common stock of Revelation Biosciences, Inc.

Summary

• Armistice Capital, LLC and Steven Boyd collectively hold 323,241 shares of Revelation Biosciences, Inc. common stock.
• This holding represents 7.80% of the total outstanding shares.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.
• The filing is made under Schedule 13G, indicating the reporting persons are not attempting to influence or change control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on ownership and does not contain operational or financial performance updates.

Positives

• Significant ownership stake of 7.80% in Revelation Biosciences, Inc. by a recognized investment manager.
• The filing is made under Schedule 13G, suggesting a passive investment approach rather than a hostile takeover attempt.

Negatives

• The Master Fund disclaims beneficial ownership due to the investment management agreement, which could imply a complex ownership structure.
• No specific strategic plans or intentions beyond holding the shares are detailed in this filing.

Risks

• Potential for future changes in beneficial ownership, which could impact share price.
• The investment manager's discretion over voting and disposition of shares could lead to unexpected market movements if decisions change.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future performance or strategy of Revelation Biosciences, Inc. It solely reports on beneficial ownership.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies, often indicating a belief in the company's potential or a strategic investment position.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Armistice Capital may influence market perception and trading activity.
• Management of Revelation Biosciences: The presence of a substantial institutional investor may lead to increased scrutiny or engagement on corporate strategy.
• Potential Investors: This filing provides information for potential investors regarding the ownership structure and significant holders.

Next Steps

• Continued monitoring of Armistice Capital's holdings and any potential future filings.
• Observation of Revelation Biosciences, Inc.'s strategic developments and financial performance.

Key Dates

Keywords

Revelation Biosciences, Armistice Capital, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Shareholder